UPLIZNA
(Inebilizumab)ApprovedMonoclonal antibody
UPLIZNA is one of 185 small molecule programs targeting Kidney Transplant. It is currently in Approved.
8
Indications
15
Total Trials
11
Active Trials
184
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
476 competitors in Kidney Transplant
#DrugCompanyPhaseTrials
1UPLIZNA
HHorizon Therapeutics Ireland DAC
Approved
Nulojix
Bristol-Myers SquibbPreclinical
Simulect
NovartisPreclinical
Medrol
PfizerPreclinical
Zinbryta
RochePreclinical
Zemplar
AbbViePreclinical
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Osmitrol
BB. Braun Medical Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neuromyelitis Optica6 trials
Pediatric1 trial
Autoimmune Disease1 trial
5 more indications
Regulatory
FDA Approval Timeline[4]
Jun 11, 2020
UPLIZNA
BLA BLA761142
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Inebilizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Approved[1]
- Company
- HHorizon Therapeutics Ireland DAC